Formosa Biomedical Technology Corp. Announces Board Approval of Q1 2026 Financial Report
NQ Score
0/100
N1 Content Completeness
90
AI Summary (NQ-processed)
Formosa Biomedical Technology Corp. (華安) announced that its Board of Directors approved the Q1 2026 financial report. The cumulative operating revenue was NT$1.391 million, with an operating loss of NT$50.802 million, a pre-tax net loss of NT$46.308 million, and a basic loss per share of NT$0.53. Total assets at the end of the period were NT$883.757 million.